福瑞股份(300049) - 2021 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2020 was ¥807,532,608.20, representing an increase of 11.26% compared to 2019[22]. - The net profit attributable to shareholders for 2020 was ¥61,905,640.52, reflecting a growth of 54.22% year-over-year[22]. - The net profit after deducting non-recurring gains and losses was ¥68,157,758.84, up 34.62% from the previous year[22]. - The total assets at the end of 2020 amounted to ¥2,290,529,206.59, which is a 10.22% increase from the end of 2019[22]. - The net assets attributable to shareholders reached ¥1,352,027,929.99, marking a 12.39% increase compared to the previous year[22]. - The basic earnings per share for 2020 was ¥0.2415, an increase of 52.22% from ¥0.1693 in 2019[22]. - The cash flow from operating activities for 2020 was ¥200,151,631.24, showing a slight increase of 4.08% from the previous year[22]. - The total revenue for the year 2021 was approximately ¥898.48 million, representing an increase of 11.26% compared to ¥807.53 million in 2020[61]. - The company achieved operating revenue of ¥332,644,187.55 in 2021, representing a growth of 4.20% compared to the previous year[41]. - The revenue from medical devices and technology accounted for 60.75% of total revenue, amounting to ¥545.81 million, with a year-on-year growth of 14.26%[61]. - The company reported a total revenue of ¥298,177,912.14 in Q4 2021, with a net profit of ¥37,295,143.30 for the same quarter[26]. Investment and Assets - The company holds a 50.13% stake in Echosens, which generated a net profit of ¥108,139,932.58 during the reporting period, contributing to 18.94% of the company's net assets[94]. - The total investment during the reporting period was ¥30,478,301.20, a decrease of 69% compared to the previous year[103]. - The company has a remaining balance of 1,328.95 million CNY in the fundraising special account[110]. - The total fair value of financial assets at the end of the period is 431,643.802 million CNY, with a cumulative investment income of 6,836,214 CNY[107]. - The company has not identified any significant impairment risks for its overseas assets, which account for 11.20% of the company's net assets[94]. - The company has a total of ¥70,559,354.36 in restricted assets due to mortgage loans[99]. - The construction in progress decreased to ¥182,145,653.25, reflecting a decline of 3.09%[94]. Research and Development - Research and development expenses for 2021 were ¥64,792,211.85, a decrease of 1.57% compared to 2020[75]. - The total R&D investment for 2021 was ¥98,668,071.46, representing 10.98% of operating revenue[79]. - The number of R&D personnel decreased by 6.10% from 82 in 2020 to 77 in 2021[79]. - The company is currently developing an upgraded version of Fibroscan to expand its product offerings and enhance global market competitiveness[76]. - The company has completed the data modeling and patent application for the FSTM project, achieving satisfactory research results[114]. Governance and Compliance - The company emphasizes that all board members attended the meeting to review the annual report, ensuring accountability for the report's accuracy and completeness[3]. - The company has maintained a governance structure that aligns with the requirements set by the China Securities Regulatory Commission, ensuring transparency and accountability[155]. - The company has a total of 11 board members, including 4 independent directors, complying with legal and regulatory requirements[153]. - The company has a financial independence system with an independent finance department and bank accounts, ensuring no interference from major shareholders in financial decisions[162]. - The company has established various committees within the board, including a strategic development committee and an audit committee, to enhance decision-making processes[153]. - The company has ensured that all shareholders have equal rights and access to information, maintaining fairness in shareholder meetings[152]. Market Strategy and Expansion - The company is focusing on the development of chronic disease treatment opportunities, following new regulations on long-term prescriptions issued by the National Health Commission[36]. - The company is actively developing new products and expanding the application scenarios of FibroScan in the medical field[45]. - The company is focusing on enhancing brand recognition and market share for its flagship product, the Compound Turtle Shell Soft Liver Tablet[43]. - The company aims to expand its market presence in liver disease and pediatric sectors while transitioning to managed healthcare[128]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share by 2025[184]. Risk Management - The company aims to enhance risk prevention by establishing a comprehensive risk control system, focusing on key areas such as drug quality management and procurement[133]. - The company faces risks from macroeconomic changes, with strategies in place to adapt to the new development pattern of domestic and international dual circulation[138]. - The company is managing the risk of raw material price fluctuations, particularly for winter worm grass, which significantly impacts production costs[142]. - The company is aware of the potential underperformance of new business developments in medical services and is actively optimizing its business models[143]. Human Resources and Remuneration - The total remuneration paid to directors, supervisors, and senior management in 2021 amounted to 6.7425 million yuan[200]. - The remuneration for directors and supervisors is determined based on performance, capability, and position level, and is approved by the board and supervisory committee[200]. - The company has established a performance evaluation scheme for senior management approved by the chairman[200]. - The company has increased its workforce by incorporating new talent and focusing on training and performance assessment[57]. Social Responsibility and Community Engagement - The company is committed to supporting social medical enterprises and improving the policy environment for their development[40]. - The company is focusing on integrating global resources to support the "Healthy China" strategy, providing comprehensive and convenient medical services[128].